Curated News
By: NewsRamp Editorial Staff
October 01, 2025
Quantum BioPharma Appoints MS Expert Dr. Jack Antel for Lucid-MS Development
TLDR
- Quantum BioPharma gains a competitive edge by appointing renowned MS expert Dr. Jack Antel to guide Lucid-MS into Phase 2 trials, accelerating development of their patented demyelination inhibitor.
- Dr. Antel will design efficacy trials for Lucid-MS, Quantum BioPharma's investigational drug that inhibits demyelination in multiple sclerosis, as it advances into Phase 2 studies.
- This appointment advances development of Lucid-MS, potentially improving treatment for multiple sclerosis patients by addressing the underlying mechanism of myelin degradation.
- Quantum BioPharma adds Dr. Jack Antel, a Dystel Award-winning neurologist with 450+ publications, to their clinical advisory team alongside Dr. Peter Stys for MS drug development.
Impact - Why it Matters
This development matters because multiple sclerosis affects over 2.8 million people worldwide with no current cure, and treatments primarily focus on managing symptoms rather than addressing the underlying demyelination process. Lucid-MS represents a novel approach that could potentially reverse myelin damage, which would be a groundbreaking advancement in MS treatment. The involvement of leading experts like Dr. Antel, who has decades of experience in MS research, significantly increases the credibility and potential success of this clinical program. For patients, this could mean a future treatment that not only slows disease progression but actually repairs the neurological damage caused by MS, potentially restoring function and improving quality of life. For the biopharmaceutical industry, successful development of such a therapy would represent a major breakthrough in neurodegenerative disease treatment.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM, CSE: QNTM) has made a significant strategic move by appointing Dr. Jack Antel, a world-renowned multiple sclerosis expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302, the company's patented investigational drug for MS treatment. Dr. Antel, who has received the prestigious Dystel Award from the National Multiple Sclerosis Society and American Academy of Neurology and authored over 450 published articles, brings exceptional expertise to guide the design of efficacy trials as Quantum advances Lucid-MS into Phase 2 clinical studies. He joins Dr. Peter Stys, Professor of Neurosciences at the University of Calgary, who continues to serve as clinical advisor, creating a formidable team of neurological experts to advance this promising treatment.
Quantum BioPharma operates as a biopharmaceutical company dedicated to building a portfolio of innovative assets for treating challenging neurodegenerative and metabolic disorders, along with alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company focuses on developing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis. The company also maintains strategic investments through FSD Strategic Investments Inc. and retains significant ownership in Unbuzzd Wellness Inc., where it receives royalty payments from the unbuzzd(TM) product while maintaining full rights to develop similar formulations for pharmaceutical and medical applications.
Investors and stakeholders can access the latest updates through the company's newsroom at the InvestorBrandNetwork, which provides comprehensive communications services through its Dynamic Brand Portfolio. This platform offers advanced wire-grade press release syndication, article and editorial distribution to over 5,000 outlets, enhanced press release optimization, and social media distribution to millions of followers. The appointment of Dr. Antel represents a crucial milestone in Quantum BioPharma's development pipeline, potentially accelerating the advancement of Lucid-MS through clinical trials and bringing new hope to the multiple sclerosis community through innovative therapeutic approaches targeting the fundamental mechanisms of the disease.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Appoints MS Expert Dr. Jack Antel for Lucid-MS Development
